La Jolla Pharmaceutical (NASDAQ:LJPC) was the target of unusually large options trading on Monday. Traders purchased 2,383 put options on the stock. This represents an increase of 936% compared to the typical daily volume of 230 put options.

A number of institutional investors have recently modified their holdings of LJPC. Janus Henderson Group PLC acquired a new stake in La Jolla Pharmaceutical during the 2nd quarter worth $25,191,000. State Street Corp raised its stake in La Jolla Pharmaceutical by 235.1% during the 2nd quarter. State Street Corp now owns 1,180,368 shares of the biopharmaceutical company’s stock worth $35,140,000 after buying an additional 828,081 shares during the period. Sectoral Asset Management Inc raised its stake in La Jolla Pharmaceutical by 649.6% during the 2nd quarter. Sectoral Asset Management Inc now owns 589,959 shares of the biopharmaceutical company’s stock worth $17,563,000 after buying an additional 511,259 shares during the period. Oak Ridge Investments LLC acquired a new stake in La Jolla Pharmaceutical during the 3rd quarter worth $14,642,000. Finally, Pictet Asset Management Ltd. acquired a new stake in La Jolla Pharmaceutical during the 3rd quarter worth $13,266,000.

Several research firms have recently issued reports on LJPC. J P Morgan Chase & Co lowered La Jolla Pharmaceutical from an “overweight” rating to an “underweight” rating and set a $20.00 price target on the stock. in a research report on Friday, December 8th. ValuEngine lowered La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, November 1st. Cowen restated a “buy” rating and issued a $55.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. Finally, Jefferies Group restated a “buy” rating and issued a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. La Jolla Pharmaceutical has a consensus rating of “Hold” and an average price target of $49.33.

Shares of La Jolla Pharmaceutical (NASDAQ:LJPC) opened at $26.59 on Thursday. La Jolla Pharmaceutical has a 12 month low of $16.41 and a 12 month high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. sell-side analysts anticipate that La Jolla Pharmaceutical will post -4.93 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “La Jolla Pharmaceutical Target of Unusually High Options Trading (LJPC)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/la-jolla-pharmaceutical-target-of-unusually-high-options-trading-ljpc.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.